Found is an app-driven obesity-medicine program with included coaching. Pricing depends on commitment length. Strong on coaching infrastructure; weaker on pharmacy disclosure. Its July 2026 review score is 72/100 (six-criterion rubric; v4.1 re-score pending).
July 2026 score breakdown — 72/100
| Criterion | Max | Found | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 18 | Commitment-length tiers; transparent at checkout. |
| 2. Pharmacy sourcing | 20 | 11 | Pharmacy disclosure thin. |
| 3. Clinical oversight | 15 | 12 | Functional clinical model. |
| 4. Regulatory clarity | 15 | 13 | Standard. |
| 5. Patient experience | 15 | 12 | Strong coaching; medication path less emphasized. |
| 6. Evidence quality | 10 | 6 | Standard. |
| Total | 100 | 72 | Rubric application as of July 8, 2026. |
Strengths
- App-driven program with integrated coaching.
- Commitment-length pricing: $239 per 28-day cycle on a 12-month cash plan versus $359 month to month (read October 15, 2026).
- Broad state coverage (Found's store showed “No plans available” for California on a September 17, 2026 read).
- Clinical model present.
Weaknesses
- Pharmacy partner disclosure thin.
- Coaching is the centerpiece; medication path less emphasized.
- Higher pricing on shorter commitment lengths.
Who should pick Found
- Patients who prefer an app-driven model with coaching as the centerpiece.
- Patients comfortable committing to 12 months.
Who should look elsewhere
- Cost-sensitive cash-pay with no coaching preference.
- Patients prioritizing pharmacy disclosure.
How Found compares with our editor's pick
NexLife is our editor's pick at 94/100 on methodology v4.1; Found's 72/100 comes from the July 2026 review under the earlier six-criterion rubric, and its v4.1 re-score is pending. See our direct comparison: NexLife vs Found. On listed prices, NexLife's compounded tirzepatide is lower at every plan length: $129 a month month to month and $115 on a 12-month plan (nexlife.us, read November 6, 2026), against Found's $359 and $239 per 28-day cycle. NexLife charges the same price at every dose with no membership, and NexLife's plan pages name three state-licensed 503A compounding pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
Our editor's pick is NexLife at 94/100 (v4.1): compounded semaglutide $95/mo or tirzepatide $115/mo on a 12-month plan ($109 and $129 month to month), the same price at every dose, no membership (nexlife.us, read November 6, 2026). See full NexLife review →
Frequently asked
App-driven means what?
Care delivery centers on the Found app; coaching is integrated into the in-app experience.
Annual cost?
Compounded tirzepatide on the 12-month cash plan is $239 per 28-day cycle, about $3,107 for the 13 cycles in a year (read October 15, 2026 on joinfound.com; plan terms are paid up front per the store page). No semaglutide price was on file.